FRC
FRC Logo
Sign InGet Access

Connect With Us

Stay updated with our latest research and insights

Fundamental Research Corp Logo

Highly ranked equity research firm providing institutional grade tools and analysis to all investors worldwide. Trusted by global investors for over 20+ years.

20+ Years
Rate us on TrustpilotLeave a review

Policies

  • Privacy Policy
  • Terms of Service
  • Disclaimer

Company

  • About Us
  • Our Team
  • Contact Us
  • Leave a Review

Resources

  • Videos
  • Research Reports
  • FAQ
  • How to use FRC

Browse

  • Stock Directory
  • Stock Screener
  • Market Intel Weekly
  • Report Archive

Trackers

  • Congress Trading
  • Senate Trading
  • Congress Net Worth
  • Commodities

© 2026 Fundamental Research Corp. All Rights Reserved.

Professional investment research since 2003

Home
Research
Get Access
Sign In
Panacos Pharmaceuticals, Inc. Stock AnalysisComprehensive stock analysis for Panacos Pharmaceuticals, Inc. (PANC) including live price, Snowflake performance metrics, financial statements, and investment research.Stock AnalysisPANC
PANC
Panacos Pharmaceuticals, Inc.
  • Company Overview
  • FRC Research
  • Financial Data
  • Peer Comparison
  • Ownership & News
PANC
Home🔹Stocks🔹Panacos Pharmaceuticals, Inc.

Panacos Pharmaceuticals, Inc.

🇺🇸PANC•OTC

Panacos Pharmaceuticals, Inc.

🇺🇸PANC•OTC
Market cap
$5.37K
Sentiment

Your view on PANC

Mkt Cap
$5.37K
Sentiment
Your view
PANC
Panacos Pharmaceuticals, Inc.
  • Company Overview
  • FRC Research
  • Financial Data
  • Peer Comparison
  • Ownership & News
PANC
Company Overview

Overview

What the company does, where it operates, and who runs it.

About Panacos Pharmaceuticals, Inc.

Industry
Biotechnology
Sector
Healthcare
CEO
John R. Barr
Headquarters
134 Coolidge Avenue, Watertown, US
Industry
Biotechnology
Sector
Healthcare
CEO
John R. Barr
Headquarters
134 Coolidge Avenue, Watertown, US
Description

Panacos Pharmaceuticals, Inc., a development stage biotechnology company, engages in the discovery and development of small-molecule oral drugs designed to treat human immunodeficiency virus (HIV) and other human viral diseases.

The company's discovery technologies focus on novel targets in the virus life cycle, including virus maturation and virus fusion. Its product pipeline includes second- and third-generation programs in HIV maturation inhibition. The company was founded in 1999 and is headquartered in Watertown, Massachusetts.

FRC Research

Media

Infographics, videos, and posts covering the company.

Financial Data

Stock Data

Price chart, volume, and trading data.

Fair Value

What FRC thinks it is worth vs. the current price.

FRC's fair value estimate for Panacos Pharmaceuticals, Inc., and the rating behind it. PANC last traded at $0.0001; the estimate is read against that market price. FRC analysts run the firm's valuation model across the companies on this platform to estimate what each one is worth, rather than republishing a consensus average. Shows the current estimate, our rating, and when it was last revised. A free account covers 7 company valuations a month; a paid subscription is unlimited.

Financial Ratios

Profitability, returns, valuation, and leverage ratios.

Valuation, profitability, liquidity and leverage ratios for Panacos Pharmaceuticals, Inc.. Starting points for Panacos Pharmaceuticals, Inc.: EPS -$0.70, beta -58.99 — an Biotechnology name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.

Dividend Analysis

Yield, payout ratio, and dividend coverage metrics.

Dividend history, yield and payout sustainability for Panacos Pharmaceuticals, Inc.. Panacos Pharmaceuticals, Inc. does not currently pay a regular dividend, so this section tracks capacity rather than history. Per-share payments, yield over time, payout ratio and growth streak, with coverage measured against free cash flow.

Earnings Analysis

EPS history, beat rate, and upcoming earnings reports.

Reported vs. expected earnings history for Panacos Pharmaceuticals, Inc.. Trailing twelve-month EPS for Panacos Pharmaceuticals, Inc. stands at -$0.70. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.

Financial Statements

Income statement, balance sheet, and cash flow statements.

Income statement, balance sheet and cash flow history for Panacos Pharmaceuticals, Inc.. Panacos Pharmaceuticals, Inc. has reported as a listed company since 2005. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.

Peer Comparison

Comparables

List of peer companies in the same industry.

Panacos Pharmaceuticals, Inc. valued side by side against its closest peers. Panacos Pharmaceuticals, Inc. is measured against Biotechnology peers within the Healthcare sector. Peer-relative multiples and operating metrics, so the valuation is read in the context of its own sector rather than in isolation.

Ownership & News

Institutional Ownership

Premium

Which funds and firms own the stock.

Which institutions hold Panacos Pharmaceuticals, Inc., and how their positions are changing. At a $5,367 market value, institutional positions materially move Panacos Pharmaceuticals, Inc.'s register. Top holders, position sizes, and quarter-over-quarter accumulation or distribution from regulatory filings. Included with FRC Premium.

Insider Trading

Premium

Recent buying and selling by company executives.

Buying and selling by Panacos Pharmaceuticals, Inc. executives and directors. Shares of Panacos Pharmaceuticals, Inc. have traded between $0.0000 and $0.0001 over the past 52 weeks — context for the timing of the transactions below. Insider transactions as disclosed to regulators, with role, size and date — the clearest read on how the people running the company are positioned. Included with FRC Premium.

Senate Trading

Premium

U.S. Senator disclosures filed under the STOCK Act.

U.S. Senate disclosures naming Panacos Pharmaceuticals, Inc.. Panacos Pharmaceuticals, Inc. is a $5,367 Healthcare company. Senators' reported transactions in this security, alongside the fundamentals — a signal most research platforms leave out entirely. Included with FRC Premium.

House Trading

Premium

U.S. Representative disclosures filed under the STOCK Act.

U.S. House of Representatives disclosures naming Panacos Pharmaceuticals, Inc.. Representatives' reported transactions in this security, shown next to the company's fundamentals. Included with FRC Premium.

News

Latest headlines and market coverage.

Latest headlines and company announcements for Panacos Pharmaceuticals, Inc.. Coverage tracks Panacos Pharmaceuticals, Inc. within Biotechnology (Healthcare). Press releases and market coverage, newest first.

Peer companies

  • ARNI — Arno Therapeutics, Inc.
  • BTTX — Better Therapeutics, Inc.
  • BXRXQ — Baudax Bio, Inc.
  • CALA — Calithera Biosciences, Inc.
  • IVBT — Innovation1 Biotech Inc.
  • IYXI — Inyx, Inc.
  • KLDO — Kaleido Biosciences, Inc.
  • ONPH — Oncology Pharma Inc.

More Biotechnology companies

  • QTTB — Q32 Bio Inc.
  • QURE — uniQure N.V.
  • RAC.AX — Race Oncology Limited
  • RAD.AX — Radiopharm Theranostics Limited
  • RADX — Radiopharm Theranostics Limited
  • RANI — Rani Therapeutics Holdings, Inc.
  • RAPP — Rapport Therapeutics, Inc. Common Stock
  • RARE — Ultragenyx Pharmaceutical Inc.
  • RASP — Actavia Life Sciences, Inc.
  • RBSH — Rebus Holdings, Inc.
  • RCAR — RenovaCare, Inc.
  • RCE.AX — Recce Pharmaceuticals Ltd

News

Latest Market News